Jan 21 2010
b3 bio inc. today announced that it has signed an agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
Dani Bolognesi, CEO and Chairman of b3 bio said, "We are delighted to continue our existing relationship with Roche through this initiative. We believe we are ideally positioned to work with academia to identify promising emerging technologies with unique therapeutic potential and to move these forward in development in conjunction with Roche."